Exsilio Therapeutics Launches with $82 Million to Develop mRNA-Based Genomic Medicines Under Tal Zaks’ Leadership
Exsilio Therapeutics, mRNA, genomic medicines, Tal Zaks, gene therapy, gene editing, lipid nanoparticle delivery, redosing, safety profile, gene therapy approval
Exsilio Emerges from Stealth with $82 Million to Revolutionize Gene Therapy
Exsilio Therapeutics, Gene Therapy, Novel Approach, mRNA, Lipid Nanoparticle Delivery, Biotech Company, Genetic Medicine
CDMO Leaders Unite for Turn-key Drug Production
Contract Development and Manufacturing Organizations (CDMOs), pharmaceutical supply chain, advanced therapies, strategic partnerships, end-to-end services, technology innovation, market consolidation, and competitive advantage.
Teladoc Research Highlights the Impact of AI-Powered ‘Nudges’ on Diabetes Management
Teladoc Health, AI-powered nudges, diabetes management, personalized health, predictive modeling, chronic condition management, virtual care
Alnylam Achieves Breakthrough in Heart Study with RNAi Therapy Vutrisiran
Alnylam, Vutrisiran, RNAi Therapy, Heart Study, ATTR Amyloidosis, Cardiomyopathy
G1 Therapeutics to Lay Off Staff After Cosela Fails in Pivotal Breast Cancer Study
G1 Therapeutics, Cosela, Breast Cancer, Layoffs, Phase 3 Trial, Trilaciclib, Metastatic Triple Negative Breast Cancer
Pfizer Secures Major Contract Over GSK for RSV Vaccine Supply in the UK
Pfizer, GSK, RSV vaccine, UK contract, Abrysvo, Arexvy
Merck KGaA Discontinues Xevinapant Program for Locally Advanced Head and Neck Cancer
Merck KGaA, Xevinapant, Head and Neck Cancer, Phase III Trial, Discontinuation, Cancer Treatment
Lilly’s Zepbound Shows Promise in Resolving Sleep Apnea in Obese Patients, Strengthening Case for Label Expansion
Zepbound, tirzepatide, sleep apnea, obesity, label expansion, Eli Lilly, SURMOUNT-OSA program, weight loss, FDA approval
UK Government Selects Pfizer Over GSK to Supply RSV Vaccine Doses
Pfizer, GSK, RSV vaccine, UK government, pharmaceutical companies, vaccine supply